Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Relapsed/Refractory Multiple Myeloma: early-phase trial registry
7 of 15 indexed Relapsed/Refractory Multiple Myeloma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,140 of 28,707 conditions by registered trial count.
15 US clinical trials · 7 currently recruiting · #1,140 of 28,707 conditions by registered trial count
Relapsed/Refractory Multiple Myeloma: 15 US clinical trials tracked, 7 recruiting.
Relapsed/Refractory Multiple Myeloma is the subject of 15 registered US clinical trials on ClinicalTrials.gov, 7 of them currently open to new participants. 3 are in Phase 3-4 (later-stage) and 12 in Phase 1-2 (earlier-stage). The most active sponsor is AbbVie, running 3 of these trials.
Enrollment posture brief
Registry condition relapsedrefractory-multiple-myeloma
OPEN 7 | RECR 47% | LATE 3 | EARLY 12 | RANK #1140 | SPON 3
Volume-matched condition peers
Nearest open-share peer: Autism (47% recruiting · 105 trials)
Relapsed/Refractory Multiple Myeloma lists 7 open slots (47% of 15 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Relapsed/Refractory Multiple Myeloma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Relapsed/Refractory Multiple Myeloma recruits in line with its size-band peers.
7 of 15 indexed trials (46.7%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Relapsed/Refractory Multiple Myeloma research.
AbbVie accounts for 3 of 15 trials (20%). 12 distinct sponsors appear on at least one study for this condition label.
-
Typical Relapsed/Refractory Multiple Myeloma enrolment sits around 103 participants.
Median target enrolment is 103 among the 15 trials that report a genuine target (sentinel values excluded). 6 of those (40%) plan for fewer than 100 participants.
-
Relapsed/Refractory Multiple Myeloma research is mostly interventional.
15 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
15 total, page 1 of 1
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
AstraZeneca
NCT07391657
A Phase 1b/2 Study of Sonrotoclax (BGB-11417) as Monotherapy and in Various Combinations With Dexamethasone Plus Carfilzomib, Dexamethasone Plus Daratumumab, and Dexamethasone Plus Pomalidomide in Multiple Myeloma
BeOne Medicines
NCT04973605
Study of ISB 2001 in Relapsed/Refractory Multiple Myeloma (TRIgnite-1)
Ichnos Sciences
NCT05862012
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
C4 Therapeutics
NCT07284758
A Study of GC012F (AZD0120), a CAR T Therapy Targeting CD19 and BCMA in Subjects With Relapsed/Refractory Multiple Myeloma
AstraZeneca
NCT05850234
CRISPR-Edited Allogeneic Anti-BCMA CAR-T Cell Therapy in Patients With Relapsed/Refractory Multiple Myeloma
Caribou Biosciences
NCT05722418
ELISA in Relapsed/Refractory MM
Massachusetts General Hospital
NCT06832865
A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused Etentamig (ABBV-383) in Combination With Anti-Cancer Regimens for the Treatment of Adult Participants With Relapsed/Refractory Multiple Myeloma
AbbVie
NCT05259839
Safety and Efficacy of ALLO-715 BCMA Allogenic CAR T Cells in in Adults With Relapsed or Refractory Multiple Myeloma (UNIVERSAL)
Allogene Therapeutics
NCT04093596
A Study of Talquetamab and Teclistamab Each in Combination With a Programmed Cell Death Receptor-1 (PD-1) Inhibitor for the Treatment of Participants With Relapsed or Refractory Multiple Myeloma
Janssen Research & Development
NCT05338775
A Study to Assess the Adverse Events and Change in Disease Activity in Adult Participants With Relapsed or Refractory Multiple Myeloma Receiving Oral ABBV-453 Tablets
AbbVie
NCT05308654
Cevostamab Following CAR T Cell Therapy for RRMM
University of Pennsylvania
NCT05801939
A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy
AbbVie
NCT02755597
Aplidin - Dexamethasone in Relapsed/Refractory Myeloma
PharmaMar
NCT01102426
Myeloma-Developing Regimens Using Genomics (MyDRUG)
Multiple Myeloma Research Consortium
NCT03732703
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 9 |
| Phase 2 | 3 |
| Phase 3 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Relapsed/Refractory Multiple Myeloma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Relapsed/Refractory Multiple Myeloma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Relapsed/Refractory Multiple Myeloma page
15 registered trials, 7 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 7 Relapsed/Refractory Multiple Myeloma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- AbbVie sponsors the most Relapsed/Refractory Multiple Myeloma trials on record, review their full trial history before evaluating a specific study. See AbbVie's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Relapsed/Refractory Multiple Myeloma condition card totals 15 registered trials; most-linked intervention Dexamethasone; top US site state New York. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.